Ketamine, originally synthesized as a structural analog of phencyclidine in 1962 and approved by the FDA as an anesthetic in 1970, has since seen an expansion into the psychiatric clinic with psychotropic uses. Its primary pharmacological profile as a nonselective N-methyl-D-aspartate (NMDA) receptor antagonist allows it to induce a unique state of dissociative anesthesia at high doses, characterized by sensory detachment and amnesia. However, research in the late 1990s suggested antidepressant effects at subanesthetic doses and catalyzed a “ketamine economy,” leading to a proliferation of for-profit clinics operating in a largely unregulated landscape. Understanding the pharmacology of ketamine is essential to appreciating why appropriate clinical monitoring is a safety imperative.
Beyond NMDA receptor blockade, ketamine interacts with a diverse array of molecular targets, including opioid, muscarinic, and nicotinic acetylcholine receptors, as well as hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. Its antidepressant actions are increasingly attributed to downstream effects, such as the upregulation of the mammalian target of rapamycin (mTOR) pathway and brain-derived neurotrophic factor (BDNF), which facilitate synaptogenesis and hippocampal plasticity. Emerging evidence also suggests that ketamine’s metabolites, such as (2R,6R)-hydroxynorketamine (HNK), may play significant roles in its therapeutic efficacy while potentially lacking the dissociative side effects of the parent compound.
At the systems level, ketamine disrupts corticocortical information transfer in a “top-down” distribution, a mechanism that underlies its anesthetic properties and likely contributes to its ability to modulate mood in treatment-resistant cases.
Despite its therapeutic promise, the pharmacology of ketamine creates an extensive side-effect profile that necessitates rigorous oversight and clinical monitoring. Common adverse reactions include transient sinus tachycardia, hypertension, and psychotomimetic symptoms such as hallucinations and derealization. Chronic exposure has been linked to dose-dependent urogenital pathologies, most notably ulcerative cystitis, and potential neurotoxicity evidenced by cognitive and semantic memory deficits. Currently, its use outside of anesthetic purposes is highly non-standardized. Unlike esketamine (Spravato), which is governed by a strict Risk Evaluation and Mitigation Strategy (REMS) requiring post-dose monitoring, generic off-label ketamine is not subject to comparable federal frameworks.
The variability in dosing protocols, ranging from gradual low-dose treatments to those intended to trigger psychedelic episodes, highlights the urgent need for standardized monitoring and safety protocols. Effective safety measures must include the monitoring of vital signs, particularly blood pressure and respiration, and the immediate availability of psychiatric support to manage perturbing dissociative experiences.
As the industry matures, regulators and state medical boards are increasingly scrutinizing operational indicators, such as individualized medical judgment and the quality of clinical documentation. The level of monitoring involved in anesthesia practice, in which ketamine plays a significant role, emphasizes patient safety. As the field grows, implementing appropriate monitoring for other uses of ketamine is essential for ensuring safety.
References
- Pribish, A., Wood, N. & Kalava, A. A review of nonanesthetic uses of ketamine. Anesthesiology Research and Practice 2020, 5798285 (2020). https://doi.org/10.1155/2020/5798285
- Megli, D. Ketamine economy: New mental health clinics pop up with few rules. NPR Shots (2024). https://www.npr.org/sections/health-shots/2024/01/30/1227633215/ketamine-economy-clinics-off-label-depression-anxiety
- Creizman, E. M. Ketamine’s regulatory reckoning: From rapid growth to enforcement. PharmExec (2026). https://www.pharmexec.com/view/ketamine-s-regulatory-reckoning-from-rapid-growth-to-enforcement
- Li, L. & Vlisides, P. E. Ketamine: 50 years of modulating the mind. Front. Hum. Neurosci. 10, 612 (2016). https://doi.org/10.3389/fnhum.2016.00612
- Zanos, P. et al. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacol. Rev. 70, 621–660 (2018). https://doi.org/10.1124/pr.117.015198